FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma
FDA also approved the cobas EZH2 Mutation Test as a companion diagnostic for tazemetostat
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1651 results
FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC
Efficacy was demonstrated in the PM1183-B-005-14 study
Severity of COVID-19 in Lung Cancer Patients
Findings from the MSKCC series
FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumours
FDA also approved a companion diagnostic for pembrolizumab
Tofacitinib for Refractory Immune-Related Colitis
JAK inhibitor shows promise in a patient with refractory immune-related complication of pembrolizumab
FDA Approves Nivolumab for Oesophageal Squamous Cell Carcinoma
Evidence for efficacy is based on the results from the ATTRACTION-3 trial
Withdrawal of Application for the EU Marketing Authorisation of Erlotinib Accord
It was intended for the treatment of non-small-cell lung cancer and pancreatic cancer
FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC
Evidence for efficacy is based on the results from the RELAY study
JAVELIN Bladder 100 Demonstrates Significantly Prolonged OS in Advanced Urothelial Cancer
Results of first-line maintenance avelumab plus best supportive care reported at ASCO 2020 Virtual Meeting
Clinical Characteristics and Risk Factors for COVID-19 Severity and Mortality Among Cancer Patients in Wuhan and Hubei
Findings from two Chinese multicentre, retrospective, cohort studies
EMA Recommends Granting a Marketing Authorisation for Biosimilar Trastuzumab
FDA Approves Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Evidence for efficacy is based on the results from the IMbrave150 study